Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
• Institutions.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Publications

Search Items: POSTMENOPAUSAL OSTEOPOROSIS, . hits: 22

2022

Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.
ESMO Open. 2022; 7(2):100426 Doi: 10.1016/j.esmoop.2022.100426 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Lorentzon, M; Branco, J; Brandi, ML; Bruyère, O; Chapurlat, R; Cooper, C; Cortet, B; Diez-Perez, A; Ferrari, S; Gasparik, A; Herrmann, M; Jorgensen, NR; Kanis, J; Kaufman, JM; Laslop, A; Locquet, M; Matijevic, R; McCloskey, E; Minisola, S; Pikner, R; Reginster, JY; Rizzoli, R; Szulc, P; Vlaskovska, M; Cavalier, E Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Adv Ther. 2019; 36(10):2811-2824 Doi: 10.1007/s12325-019-01063-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Minisola, S; Marin, F; Kendler, DL; Geusens, P; Zerbini, CAF; Russo, LA; Casado, E; Fahrleitner-Pammer, A; Stepan, JJ; Lespessailles, E; Moericke, R; Bagur, A; Lakatos, P; López-Romero, P; Body, JJ Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Arch Osteoporos. 2019; 14(1):10-10 Doi: 10.1007/s11657-019-0561-x
Web of Science PubMed FullText FullText_MUG

 

2018

Geusens, P; Marin, F; Kendler, DL; Russo, LA; Zerbini, CA; Minisola, S; Body, JJ; Lespessailles, E; Greenspan, SL; Bagur, A; Stepan, JJ; Lakatos, P; Casado, E; Moericke, R; López-Romero, P; Fahrleitner-Pammer, A Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
J Bone Miner Res. 2018; 33(5):783-794 Doi: 10.1002/jbmr.3384 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Thomasius, F; Baum, E; Bernecker, P; Bocker, W; Brabant, T; Clarenz, P; Demary, W; Dimai, HP; Engelbrecht, M; Engelke, K; Fratermann, U; Grieser, T; Gulich, M; Hadji, P; Henning, J; Jehle, PM; Kern, PM; Ketteler, M; Klatt, G; Kraenzlin, M; Maus, U; Meier, C; Moser, U; Muller, D; Peichl, P; Pfeifer, M; Rintelen, B; Rueger, JM; Schober, HC; Schoffel, D; Schwarz, H; Siggelkow, H; Suhm, N; Wiese, KG; Wortler, K; Kurth, AA DVO Guideline 2017 for the Prophylaxis, Diagnosis and Treatment of Osteoporosis in postmenopausal Women and Men Short Version
OSTEOLOGIE. 2018; 27(3): 154-160. Doi: 10.1055/s-0038-1673537 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

2017

Diez-Perez, A; Naylor, KE; Abrahamsen, B; Agnusdei, D; Brandi, ML; Cooper, C; Dennison, E; Eriksen, EF; Gold, DT; Guañabens, N; Hadji, P; Hiligsmann, M; Horne, R; Josse, R; Kanis, JA; Obermayer-Pietsch, B; Prieto-Alhambra, D; Reginster, JY; Rizzoli, R; Silverman, S; Zillikens, MC; Eastell, R; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Osteoporos Int. 2017; 28(3):767-774 Doi: 10.1007/s00198-017-3906-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Paschalis, EP; Gamsjaeger, S; Hassler, N; Fahrleitner-Pammer, A; Dobnig, H; Stepan, JJ; Pavo, I; Eriksen, EF; Klaushofer, K Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.
Bone. 2017; 95(2):41-46 Doi: 10.1016/j.bone.2016.11.002
Web of Science PubMed FullText FullText_MUG

 

2015

Hadji, P; Papaioannou, N; Gielen, E; Feudjo Tepie, M; Zhang, E; Frieling, I; Geusens, P; Makras, P; Resch, H; Möller, G; Kalouche-Khalil, L; Fahrleitner-Pammer, A Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Osteoporos Int. 2015; 26(10):2479-2489 Doi: 10.1007/s00198-015-3164-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Pahr, D; Patsch, JM; Amrein, K; Misof, BM; Kaider, A; Resch, H; Pietschmann, P Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Calcif Tissue Int. 2015; 96(6): 477-489. Doi: 10.1007/s00223-015-0003-8
Web of Science PubMed FullText FullText_MUG

 

2014

Kerschan-Schindl, K; Mikosch, P; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P Current controversies in clinical management of postmenopausal osteoporosis.
Exp Clin Endocrinol Diabetes. 2014; 122(8):437-444 Doi: 10.1055/s-0034-1374610
Web of Science PubMed FullText FullText_MUG

 

Roux, C; Hofbauer, LC; Ho, PR; Wark, JD; Zillikens, MC; Fahrleitner-Pammer, A; Hawkins, F; Micaelo, M; Minisola, S; Papaioannou, N; Stone, M; Ferreira, I; Siddhanti, S; Wagman, RB; Brown, JP Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Bone. 2014; 58(2):48-54 Doi: 10.1016/j.bone.2013.10.006 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Kerschan-Schindl, K; Haschka, J; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?
Horm Metab Res. 2013; 45(9):621-628 Doi: 10.1055/s-0033-1345207
Web of Science PubMed FullText FullText_MUG

 

Ljunggren, Ö; Barrett, A; Stoykov, I; Langdahl, BL; Lems, WF; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Jakob, F; Karras, D; Marin, F Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
BMC Musculoskelet Disord. 2013; 14(8):251-251 Doi: 10.1186/1471-2474-14-251 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Muschitz, C; Fahrleitner-Pammer, A; Huber, J; Preisinger, E; Kudlacek, S; Resch, H Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Wien Med Wochenschr. 2012; 162(17-18):374-379 Doi: 10.1007/s10354-012-0116-x
PubMed FullText FullText_MUG

 

Walsh, JB; Lems, WF; Karras, D; Langdahl, BL; Ljunggren, O; Fahrleitner-Pammer, A; Barrett, A; Rajzbaum, G; Jakob, F; Marin, F Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
Calcif Tissue Int. 2012; 90(5):373-383 Doi: 10.1007/s00223-012-9590-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Rintelen, B; Bobacz, K; Höfle, G; Peichl, P; Rainer, F; Weber, K; Gaugg, M; (Arbeitsgruppe Osteologie der Österreichischen Gesellschaft für Rheumatologie und Rehabilitation – ÖGR) [Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines].
Wien Klin Wochenschr. 2011; 123(21-22):633-644 Doi: 10.1007/s00508-011-0042-8
Web of Science PubMed FullText FullText_MUG

 

2010

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Wien Med Wochenschr. 2010; 160(21-22):586-589 Doi: 10.1007/s10354-010-0840-z
PubMed FullText FullText_MUG

 

2009

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34. Doi: 10.1007/s10354-009-0656-x
PubMed FullText FullText_MUG Google Scholar

 

Eastell, R; Black, DM; Boonen, S; Adami, S; Felsenberg, D; Lippuner, K; Cummings, SR; Delmas, PD; Palermo, L; Mesenbrink, P; Cauley, JA; HORIZON Pivotal Fracture Trial Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
J Clin Endocrinol Metab. 2009; 94(9): 3215-3225. Doi: 10.1210/jc.2008-2765 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2005

Dimai, HP Strontium ranelate: a novel concept for the treatment of osteoporosis
WIEN KLIN WOCHENSCHR. 2005; 117(21-22): 728-738. Doi: 10.1007/s00508-005-0471-3
Web of Science PubMed FullText FullText_MUG

 

2002

Reid, IR; Brown, JP; Burckhardt, P; Horowitz, Z; Richardson, P; Trechsel, U; Widmer, A; Devogelaer, JP; Kaufman, JM; Jaeger, P; Body, JJ; Brandi, ML; Broell, J; Di Micco, R; Genazzani, AR; Felsenberg, D; Happ, J; Hooper, MJ; Ittner, J; Leb, G; Mallmin, H; Murray, T; Ortolani, S; Rubinacci, A; Saaf, M; Samsioe, G; Verbruggen, L; Meunier, PJ Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
N Engl J Med. 2002; 346(9):653-661 Doi: 10.1056/NEJMoa011807 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2001

Neer, RM; Arnaud, CD; Zanchetta, JR; Prince, R; Gaich, GA; Reginster, JY; Hodsman, AB; Eriksen, EF; Ish-Shalom, S; Genant, HK; Wang, O; Mitlak, BH (Study group members, Leb, G; Dobnig, H; Fahrleitner, A) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N ENGL J MED. 2001; 344(19): 1434-1441. Doi: 10.1056%2FNEJM200105103441904 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint